This review aims to provide a comprehensive overview of the significant Clostridioides difficile molecular typing techniques currently employed in research and medical communities. The main objectives of this review are to describe the key molecular typing methods utilized in C. difficile …

The majority of recently published studies indicate a greater incidence and mortality due to Clostridioides difficile infection (CDI) in patients with chronic kidney disease (CKD). Hospitalization, older age, the use of antibiotics, immunosuppression, proton pump inhibitors (PPI), and chronic …

According to GlobalData, the clostridium difficile tests market in Taiwan was valued at 0.36 in 2022

According to GlobalData, the clostridium difficile tests market in Russia was valued at 5.40 in 2022

According to GlobalData, the clostridium difficile tests market in Turkey was valued at 3.80 in 2022

Although pediatric CDI epidemiology in Saudi Arabia doesn't impose a burden on the healthcare system, it should be noted that not all hospitals follow CDI diagnostic recommendations of international guidelines, which may result in cases underreporting. However, due to the presumed low CDI prevalence …

The infectious disease diagnostic company MeMed is taking a big step toward a larger market of point-of-care settings, courtesy of a new FDA green light for its test that distinguishes between vira | The infectious disease diagnostic company MeMed is taking a big step toward a larger market, courtesy of an FDA green light for its test that distinguishes between viral and bacterial cases.

The global Clostridium Diagnostics Market is anticipated to grow at a 12.2% CAGR from 2022 to 2032, from US$ 2.5 billion to US$ 7.8 billion. The market saw a 13.6% CAGR between 2015 and 2021. The market is expanding as a result of increased awareness-raising activities for clostridium-related illnesses and their rising prevalence. There has been an increased focus of players in […]

A testing strategy of PCR plus toxin EIA helped predict recurrent CDI.

A testing strategy of PCR plus toxin EIA helped predict recurrent CDI.

A-two-step-algorithm-for-Clostridioides-difficile-infection-testing-may-improve-detection-and-reduce-unnecessary-treatment

MicroRNA has shown the potential to more effectively and accurately identify C. difficile infections and manage it after diagnosis.

Misclassification of Clostridioides difficile colonization as hospital-onset C. difficile infection (HO-CDI) can lead to unnecessary treatment of patients and substantial financial penalties for hospitals. We successfully implemented mandatory C. difficile PCR testing approval a …

Clostridioides difficile infection can be difficult to treat, but increasing disease awareness can improve screening and treatment outcomes.

ORLANDO — A hospital reduced the rate of hospital-onset cases of Clostridioides difficile infection with a standardized system for early recognition and testing, researchers found.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.

CT value was an acceptable predictor for EIA toxin but less so for clinical severity. Our study potentially supports a diagnostic algorithm including CT value to reduce the number of EIA toxin assays performed.

CT value was an acceptable predictor for EIA toxin but less so for clinical severity. Our study potentially supports a diagnostic algorithm including CT value to reduce the number of EIA toxin assays performed.

There are no established standards for the diagnosis of Clostridioides difficile infection (CDI), even though the importance of this infection in humans is well known. The effectiveness of the commercially available techniques, which are all standardized for use with human feces, is also limi …

Clostridioides difficile (formerly called Clostridium difficile, C. difficile) infection (CDI) is listed as an urgent threat on the 2019 antibiotic resistance threats report in the United States by the Centers for Disease Control and Prevention. Early detection and appropriate d …

Clostridioides difficile (formerly called Clostridium difficile, C. difficile) infection (CDI) is listed as an urgent threat on the 2019 antibiotic resistance threats report in the United States by the Centers for Disease Control and Prevention. Early detection and appropriate d …

Clostridioides difficile is one of the leading pathogens causing nosocomial infection. The infection can range from mild to severe, and rapid identification is pivotal for early clinical diagnosis and appropriate treatment. Here, a genetic testing platform for toxins, referred to as OC-MAB (orthogon …

Clostridioides difficile is one of the leading pathogens causing nosocomial infection. The infection can range from mild to severe, and rapid identification is pivotal for early clinical diagnosis and appropriate treatment. Here, a genetic testing platform for toxins, referred to as OC-MAB (orthogon …

The PathFlow C. difficile GDH & Tox A/B Combi Cassette simultaneously detects three distinct antigens in faecal specimens for C. difficile; GDH, Toxin A and Toxin B.

Two-step Clostridioides difficile testing was associated with decreased reported incidence of hospital-onset C. difficile infection and C. difficile-specific antibiotic use, researchers found.

The global Clostridium Diagnostics Market revenue is projected to secure US$ 7.8 Billion by 2032 while recording a CAGR of 12.2% during the forecast period. The growth of the market can be attributed to the growing prevalence of clostridium-related diseases and the growing awareness campaigns lau...

There is limited utility of bedside clinical examination alone in detecting C. difficile infection. Accurate diagnosis of C. difficile infection requires thoughtful clinical assessment for interpretation of microbiologic testing in all suspected cases.

The 24-hour autocancellation of uncollected C. difficile orders reduced testing but did not result in reported HAI reduction.

A study of hospitalized patients with diarrhea found that collecting stool samples and testing all of them identified almost 30% more cases of C. diff than the standard of care.